A flow-cytometric method for continuous measurement of intracellular Ca(2+) concentration.
Alterations in intracellular Ca(2+) concentration are amongst the most rapid responses to a variety of stimuli in mammalian cells. In the nervous system in particular, responses occur within nanoseconds. A major challenge in intracellular Ca(2+) analysis is to achieve measurements within this very fast time frame. To date, the dynamic intracellular Ca(2+) concentration has been monitored by confocal microscopy, plate-based assays, spectrofluorometry, and flow cytometry, although there are issues with the number of cells analyzed or gaps in recording due to the addition of compounds, with significant loss of detail of a rapid Ca(2+) response. The new generation of flow cytometers (such as Accuri C6) resolves this problem by allowing the addition of test compounds with continuous monitoring of thousands of cells, providing a method for dynamic Ca(2+) measurements. This system was tested with commonly used Ca(2+) modulating agents in C6 glioma cells. Thapsigargin (TG), a blocker of Ca(2+) uptake into the endoplasmic reticulum (ER), causes a significant increase in the intracellular calcium concentration via ER emptying followed by Ca(2+) entry via store-operated Ca(2+) channels (SOCC). This well-established pathway can be partially inhibited by 2-aminoethoxydiphenyl borate (2-APB), a blocker of SOCC. Both the increase with TG alone and the partial increase when coincubated with 2-APB were observed with continuous recording along with calibration curves using an Accuri C6 flow cytometer. With these new cytometers, dynamic Ca(2+) concentration measurement becomes extremely accessible and accurate, while also providing extensive and valuable data regarding population health and responsiveness.
Vines
Alice
A
UCD School of Biomolecular and Biomedical Science, UCD-Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
McBean
Gethin J
GJ
Blanco-Fernández
Alfonso
A
D000818:Animals; D001896:Boron Compounds / Q000494:pharmacology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry / Q000379:methods*; D005910:Glioma / Q000188:drug therapy / Q000378:metabolism*; D051381:Rats; D019284:Thapsigargin / Q000494:pharmacology
D001896:Boron Compounds; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D004791:Enzyme Inhibitors; D019284:Thapsigargin; C109986:2-aminoethoxydiphenyl borate; D002118:Calcium